Comparing Alder BioPharmaceuticals (ALDR) & Its Peers

Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Alder BioPharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, profitability, valuation and risk.

Profitability

This table compares Alder BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alder BioPharmaceuticals N/A -93.14% -84.14%
Alder BioPharmaceuticals Competitors -5,355.33% -433.53% -38.99%

Risk and Volatility

Alder BioPharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ peers have a beta of 1.83, meaning that their average stock price is 83% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Alder BioPharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alder BioPharmaceuticals 0 1 11 0 2.92
Alder BioPharmaceuticals Competitors 845 3193 11581 230 2.71

Alder BioPharmaceuticals presently has a consensus price target of $30.58, suggesting a potential upside of 191.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.11%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Alder BioPharmaceuticals is more favorable than its peers.

Valuation & Earnings

This table compares Alder BioPharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alder BioPharmaceuticals $110,000.00 -$156.25 million -1.96
Alder BioPharmaceuticals Competitors $284.30 million $34.29 million 129.23

Alder BioPharmaceuticals’ peers have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

96.9% of Alder BioPharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.6% of Alder BioPharmaceuticals shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alder BioPharmaceuticals beats its peers on 7 of the 12 factors compared.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

What are top analysts saying about Alder BioPharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alder BioPharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit